GlassScriptPhysician profile
Tamela Tripp
NPI 1407842826
$3,641.84
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $644 · 2021: $1,448 · 2022: $698 · 2023: $42.88 · 2024: $39.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $498.64 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $280.82 | 2019-2021 | |
| Amgen INC. | $272.37 | 2019-2022 | |
| Janssen Biotech, INC. | $243.54 | 2020-2022 | |
| Leo Pharma INC. | $176.31 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $166.18 | 2021 | |
| Genzyme Corporation | $158.26 | 2019-2022 | |
| Genentech USA, INC. | $144.79 | 2019 | |
| Lilly USA, LLC | $140.13 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $139.95 | 2019-2021 | |
| Pfizer INC. | $134.35 | 2019-2022 | |
| Almirall LLC | $133.22 | 2022 | |
| Celgene Corporation | $124.95 | 2019 | |
| Galderma Laboratories, L.P. | $87.29 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $85.91 | 2019-2021 | |
| Biofrontera INC. | $60.20 | 2020-2022 | |
| Incyte Corporation | $56.26 | 2021-2023 | Opzelura |
| Dermira, INC. | $54.35 | 2020-2021 | |
| Allergan, INC. | $48.48 | 2019-2022 | |
| Mission Pharmacal Company | $16.06 | 2019 | |
| Epi Health, LLC | $15.59 | 2020 | |
| Prugen, INC. Pharmaceuticals | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamela Tripp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.